Sermorelin and GLP-1 Medications: What to Know About Combination Therapy
March 2026
Sermorelin may be prescribed alongside GLP-1 receptor agonists such as semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) under appropriate physician supervision. The clinical interest in this combination centers on lean mass preservation during pharmacologic weight loss.
Body-composition research from major GLP-1 trials suggests that while fat loss accounts for most of the reduction in body weight, a meaningful portion may also come from lean tissue. Because skeletal muscle plays an important role in metabolic rate, physical function, and long-term weight maintenance, some clinicians are exploring complementary strategies to help patients lose fat while maintaining muscle.
Sermorelin works by stimulating the body’s natural production of growth hormone, which may support muscle maintenance, recovery, and overall body-composition goals during periods of caloric deficit.
Overview of Sermorelin and GLP-1 Therapy
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It acts at the level of the pituitary gland to promote pulsatile release of human growth hormone, which then stimulates IGF-1 production. This physiologic cascade is associated with effects on lean tissue, metabolism, and recovery.
Historically, sermorelin was FDA-approved under the brand name Geref for pediatric growth hormone deficiency. Although the branded product was later discontinued for commercial reasons, sermorelin remains available through licensed compounding pharmacies and is prescribed off-label in adults based on clinical judgment. It is typically administered as a subcutaneous injection, often in the evening to align with natural growth hormone rhythms.
GLP-1 receptor agonists, including semaglutide and tirzepatide, act through incretin pathways. They enhance glucose-dependent insulin secretion, suppress glucagon release, delay gastric emptying, and increase satiety. These effects contribute to sustained caloric reduction and meaningful weight loss in appropriately selected patients.
The Lean Mass Question During GLP-1 Weight Loss
GLP-1 medications are among the most effective pharmacologic tools currently available for obesity and metabolic disease management. Clinical trials have demonstrated significant improvements in weight, glycemic control, and cardiometabolic risk factors.
However, body-composition analyses have raised an important clinical consideration: not all weight loss represents fat loss.
For example, in the STEP-1 trial evaluating semaglutide 2.4 mg for chronic weight management, participants experienced substantial reductions in total body weight alongside decreases in lean mass measured through imaging-based analyses.
This observation does not diminish the value of GLP-1 therapy. Rather, it highlights the importance of considering strategies that may help patients preserve metabolically active tissue while achieving fat reduction.
Growth hormone signaling plays a role in protein synthesis and tissue maintenance. For this reason, some clinicians are evaluating whether agents that stimulate endogenous growth hormone release — such as sermorelin — may support more favorable body-composition outcomes when used alongside GLP-1 medications.
The clinical goal is straightforward: reduce fat mass while maintaining muscle.
Mechanisms of Action: How Sermorelin and GLP-1s Complement Each Other
Sermorelin and GLP-1 receptor agonists act through distinct physiologic pathways.
- Sermorelin binds to GHRH receptors in the pituitary, promoting natural pulses of growth hormone release. Growth hormone then increases IGF-1 activity, supporting protein synthesis, muscle repair, and fat metabolism. Because this occurs through normal endocrine feedback loops, hormone levels typically remain within physiologic ranges.
- GLP-1 medications mimic endogenous incretin hormones released after meals. Activation of GLP-1 receptors improves insulin sensitivity, reduces appetite signals, and slows gastric emptying. The result is reduced caloric intake and improved metabolic regulation.
When combined under clinical supervision, these therapies address weight management from complementary angles. GLP-1 agents drive fat loss by creating a sustained energy deficit, while sermorelin may help support the hormonal environment associated with lean mass maintenance during that deficit.
Potential Clinical Benefits
When carefully prescribed and monitored, combination therapy may offer several practical considerations for patients focused on body composition and metabolic health.
Muscle Support
Endogenous growth hormone signaling is associated with preservation of lean tissue during weight loss and may help limit excessive catabolism in prolonged caloric deficit.
Fat Reduction
GLP-1 medications reduce appetite and support adherence to dietary changes. Growth hormone activity also contributes to lipolysis, meaning both therapies influence fat metabolism through different pathways.
Metabolic Function
Maintaining lean mass during weight loss may help sustain resting metabolic rate and improve long-term weight maintenance. Improved insulin sensitivity and glycemic control are also potential downstream benefits of GLP-1 therapy.
Qualification and Individualized Care
Determining whether combination therapy is appropriate requires structured clinical evaluation. This typically includes:
- Review of medical history and current medications
- Assessment of metabolic and endocrine markers
- Consideration of treatment goals and body-composition priorities
- Development of a personalized dosing and monitoring plan
If prescribed, sermorelin is dispensed through licensed compounding pharmacies and requires ongoing follow-up to assess efficacy and tolerability.
Safety Considerations
Both therapies are generally well tolerated when used appropriately, but clinicians and patients should remain aware of potential adverse effects.
Common GLP-1-related effects:
- Nausea or gastrointestinal symptoms during dose escalation
- Delayed gastric emptying
- Glycemic changes in patients on concomitant diabetes therapy
Possible sermorelin-related effects:
- Injection-site irritation
- Headache or flushing
- Transient changes in glucose regulation
Patients with a history of pancreatitis, active malignancy, severe gastrointestinal disease, or untreated endocrine conditions should undergo careful risk assessment before initiating either therapy. Persistent or severe symptoms should prompt clinical reassessment.
Considering Sermorelin for Patients on GLP-1 Therapy?
Optimizing body composition during GLP-1 therapy requires thoughtful clinical planning. For patients at risk of excessive lean mass loss, additional approaches such as sermorelin may be worth evaluating.
To learn more about prescribing compounded sermorelin or to review available dosing options, contact a pharmacist or access our Practitioner Portal.